Remus Pharmaceuticals is a pharmaceutical company that does not own a single factory. Instead, it spots off-patent drugs with untapped potential, handles the regulatory paperwork to get them approved across more than 40 countries, and then has them made by contract manufacturers - an asset-light model built for speed, not heavy industry. Founded in Ahmedabad in 2015 and listed in 2023, the company was shaped by a founding team that includes pharmacists and regulatory specialists who built the business around a single recurring idea: find complex, niche formulations that few others bother with, file dossiers faster than rivals, and capture first-mover advantage before the market turns commoditized.
Business segments
Two engines feed each other - a core export-and-branding business that files over 50 dossiers a month to put complex generics into emerging markets, and a US-based subsidiary that sources the very reference drugs those generics are tested against.
1. Finished formulations: the dossier factory that puts complex generics into emerging markets
The company earns by identifying off-patent molecules, getting them registered country by country, and then exporting branded or partner-labelled medicines - it sells regulatory speed and market access, not manufacturing capacity.
- A dossier machine, not a pill press - an in-house team of over 30 regulatory professionals prepares and submits more than 50 dossiers every month, maintaining a live portfolio of 903 approved products and another 1,400 under evaluation across the world. Because each country demands its own registration (a process that can take six months to three years), the sheer volume of filings is what opens doors before competitors arrive.
- Two ways to sell the same product - the B2B arm (roughly 86% of revenue) supplies finished medicines to global distributors who sell them under their own brands, requiring no inventory or promotional spend from Remus; the B2C arm sells under the company's own "Relius" brand through its subsidiaries in Bolivia and Guatemala, capturing the full value chain at higher margins.
- Complex products, fewer rivals - over 95% of exports are advanced and niche formulations, spanning injectables, inhalers, pre-filled syringes, dermal patches, and oncology biosimilars rather than simple tablets. The company deliberately avoids commoditized "me-too" markets, which is why its gross margins sit in the 55-60% range - well above what plain-vanilla generics typically command.
- Latin America first, then the rest - the largest dossier footprint is in Latin America, with 1,693 registrations filed, approved or under review, and the top five B2B markets by revenue are Bolivia, Guatemala, the Dominican Republic, Ecuador and Myanmar. The company has also begun placing oncology products in the Philippines and Vietnam, CNS patches in Venezuela, and anti-TB tenders in North Macedonia - each a small beachhead in a new geography.
- A pipeline mapped to 2038 - the company maintains data on molecules going off-patent for more than a decade ahead, and already has over 850 dossiers ready-to-file for various geographies. That forward visibility, combined with R&D spending kept to 2-3% of turnover, means the launch calendar is stocked years in advance without a heavy cost burden.
2. Reference Listed Drug distribution: the US-sourced comparator that feeds the generics industry
Espee Global Holdings, a majority-owned US subsidiary, supplies the original branded drugs that generic companies worldwide need to buy in order to run their bioequivalence tests - a high-turnover, low-margin gateway into the American market.
- The drug industry's librarian - Espee is one of the world's largest distributors of Reference Listed Drugs (the original, FDA-approved version of a medicine that a generic must be tested against), sourcing hard-to-access REMS, specialty, orphan and biosimilar products for over 300 customers across more than 30 countries.
- Clients are the companies Remus competes with - the customer list includes top generic pharmaceutical firms, biopharma innovators, R&D organisations and contract manufacturers, all of whom need authentic reference products to conduct the studies required for their own regulatory filings.
- Thin margin, high return on equity - the business operates at roughly 8% gross margin, a fraction of the formulations business, but is described as a high-ROE operation because it turns inventory quickly and requires little capital.
- A back door into the US - the 2024 acquisition gave Remus its first operational foothold in the United States and established direct relationships with top global pharmaceutical companies, creating a source of market intelligence that sits upstream of the company's own generic launches.
Group structure and partners
The company runs a lean, subsidiary-light structure - two Latin American entities carry the B2C brand, one US subsidiary runs the reference-drug business, and everything else is outsourced to contract manufacturers.
- Two B2C subsidiaries in Latin America - Relius Pharma SRL in Bolivia and Relius Pharmaceuticals LTDA in Guatemala, each 99%-owned, handle last-mile distribution, pharmacy-channel relationships, brand building and national tender participation under the "Relius" name.
- A Singapore branch for regional reach - a branch office was registered in December 2025 to explore new business opportunities in Southeast Asia.
- Manufacturing is entirely outsourced - the company works with over 30 contract manufacturing partners who hold the accreditations required by each importing country, so Remus itself carries no plant, no equipment and only 86 employees as of March 2025.